|
Variables
|
|---|
|
Age (years), median (range)
|
56 (36–74)
|
|
Neoadjuvant chemotherapy (%)
|
14 (12.5%)
|
|
Histology
|
|
High-grade serous carcinoma
|
95 (84.8%)
|
|
Clear cell carcinoma
|
9 (8.03%)
|
|
Endometrioid
|
2 (1.8%)
|
|
Mucinous
|
2 (1.8%)
|
|
Carcinosarcoma
|
3 (2.7%)
|
|
Squamous
|
1 (0.9%)
|
|
FIGO stage (%)
|
|
I
|
15 (13.4%)
|
|
II
|
5 (4.5%)
|
|
III
|
64 (57.1%)
|
|
IV
|
28 (25.0%)
|
|
Pre-treatment serum CA 125 (U/mL), median (range)
|
746.4 (10–5000)a
|
|
Residual disease (%)
|
|
≤ 1 cm (optimal)
|
88 (78.6%)
|
|
> 1 cm (suboptimal)
|
24 (21.4%)
|
|
Platinum response (%)b
|
|
Sensitive
|
45 (76.3%)
|
|
Resistant
|
14 (23.7%)
|
- aThe upper limit of CA 125 detection is 5000
- bA total of 59 patients were available for platinum response assessment
- Abbreviations: FIGO The International Federation of Gynecology and Obstetrics, CA125 Cancer Antigen
